<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">70002</article-id><article-id pub-id-type="doi">10.7554/eLife.70002</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>The alpha/B.1.1.7 SARS-CoV-2 variant exhibits significantly higher affinity for ACE-2 and requires lower inoculation doses to cause disease in K18-hACE2 mice</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-230453"><name><surname>Bayarri-Olmos</surname><given-names>Rafael</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-237636"><name><surname>Johnsen</surname><given-names>Laust Bruun</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-237637"><name><surname>Idorn</surname><given-names>Manja</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-237638"><name><surname>Reinert</surname><given-names>Line S</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-208567"><name><surname>Rosbjerg</surname><given-names>Anne</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-251388"><name><surname>Vang</surname><given-names>Søren</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-237639"><name><surname>Hansen</surname><given-names>Cecilie Bo</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-237640"><name><surname>Helgstrand</surname><given-names>Charlotte</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-237641"><name><surname>Bjelke</surname><given-names>Jais Rose</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-237642"><name><surname>Bak-Thomsen</surname><given-names>Theresa</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-162332"><name><surname>R Paludan</surname><given-names>Søren</given-names></name><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-197819"><name><surname>Garred</surname><given-names>Peter</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-236888"><name><surname>Skjoedt</surname><given-names>Mikkel-Ole</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-1306-6482</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="other" rid="par-2"/><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Laboratory of Molecular Medicine, Department of Clinical Immunology</institution>, <institution>Copenhagen University Hospital</institution>, <addr-line><named-content content-type="city">Copenhagen</named-content></addr-line>, <country>Denmark</country></aff><aff id="aff2"><institution>Novo Nordisk A/S</institution>, <addr-line><named-content content-type="city">Måløv</named-content></addr-line>, <country>Denmark</country></aff><aff id="aff3"><institution content-type="dept">Department of Biomedicine</institution>, <institution>Aarhus University</institution>, <addr-line><named-content content-type="city">Århus</named-content></addr-line>, <country>Denmark</country></aff><aff id="aff4"><institution content-type="dept">Recombinant Protein and Antibody Laboratory</institution>, <institution>Copenhagen University Hospital</institution>, <addr-line><named-content content-type="city">Copenhagen</named-content></addr-line>, <country>Denmark</country></aff><aff id="aff5"><institution content-type="dept">Department of Molecular Medicine</institution>, <institution>Aarhus University Hospital</institution>, <addr-line><named-content content-type="city">Aarhus</named-content></addr-line>, <country>Denmark</country></aff><aff id="aff6"><institution content-type="dept">Department of Biomedicine</institution>, <institution>Aarhus University</institution>, <addr-line><named-content content-type="city">Aarhus</named-content></addr-line>, <country>Denmark</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-185614"><name><surname>Sato</surname><given-names>Kei</given-names></name><role>Reviewing editor</role><aff><institution>The Institute of Medical Science, The University of Tokyo</institution>, <country>Japan</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>moskjoedt@sund.ku.dk</email> (MS);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>25</day><month>11</month><year>2021</year></pub-date><volume>10</volume><elocation-id>e70002</elocation-id><history><date date-type="received"><day>04</day><month>05</month><year>2021</year></date><date date-type="accepted"><day>24</day><month>11</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Bayarri-Olmos et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Bayarri-Olmos et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-70002-v2.pdf"/><abstract><p>The alpha/B.1.1.7 SARS-CoV-2 lineage emerged in autumn 2020 in the United Kingdom and transmitted rapidly until winter 2021 when it was responsible for most new COVID-19 cases in many European countries. The incidence domination was likely due to a fitness advantage that could be driven by the RBD residue change (N501Y), which also emerged independently in other Variants of Concern such as the beta/B.1.351 and gamma/P.1 strains. Here we present a functional characterization of the alpha/B.1.1.7 variant and show an eight-fold affinity increase towards human ACE-2. In accordance with this, transgenic hACE-2 mice showed a faster disease progression and severity after infection with a low dose of B.1.1.7, compared to an early 2020 SARS-CoV-2 isolate. When challenged with sera from convalescent individuals or anti-RBD monoclonal antibodies, the N501Y variant showed a minor, but significant elevated evasion potential of ACE-2/RBD antibody neutralization. The data suggest that the single asparagine to tyrosine substitution remarkable rise in affinity may be responsible for the higher transmission rate and severity of the B.1.1.7 variant.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100002808</institution-id><institution>Carlsbergfondet</institution></institution-wrap></funding-source><award-id>CF20-0045</award-id><principal-award-recipient><name><surname>Bayarri-Olmos</surname><given-names>Rafael</given-names></name><name><surname>Rosbjerg</surname><given-names>Anne</given-names></name><name><surname>Garred</surname><given-names>Peter</given-names></name><name><surname>Skjoedt</surname><given-names>Mikkel-Ole</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100009708</institution-id><institution>Novo Nordisk Fonden</institution></institution-wrap></funding-source><award-id>NFF205A0063505</award-id><principal-award-recipient><name><surname>Bayarri-Olmos</surname><given-names>Rafael</given-names></name><name><surname>Rosbjerg</surname><given-names>Anne</given-names></name><name><surname>Garred</surname><given-names>Peter</given-names></name><name><surname>Skjoedt</surname><given-names>Mikkel-Ole</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100009708</institution-id><institution>Novo Nordisk Fonden</institution></institution-wrap></funding-source><award-id>NNF20OC0063436</award-id><principal-award-recipient><name><surname>Bayarri-Olmos</surname><given-names>Rafael</given-names></name><name><surname>Rosbjerg</surname><given-names>Anne</given-names></name><name><surname>Garred</surname><given-names>Peter</given-names></name><name><surname>Skjoedt</surname><given-names>Mikkel-Ole</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100009708</institution-id><institution>Novo Nordisk Fonden</institution></institution-wrap></funding-source><award-id>NNF20SA0064201</award-id><principal-award-recipient><name><surname>Bayarri-Olmos</surname><given-names>Rafael</given-names></name><name><surname>Rosbjerg</surname><given-names>Anne</given-names></name><name><surname>Garred</surname><given-names>Peter</given-names></name><name><surname>Skjoedt</surname><given-names>Mikkel-Ole</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: The Danish Animal Experiments Inspectorate has approved the experimental animal procedures and were carried out in accordance with the Danish Animal Welfare Act for the Care and Use of Animals for Scientific Purposes. (License ID 2019-15-0201-00090 and 2020-15-0201-00726). All procedures followed the recommendations of the Animal Facilities at the Universities of Copenhagen and Aarhus.</p></fn><fn fn-type="other"><p>Human subjects: The collection and use of blood samples have been approved by the Regional Ethical Committee of the Capital Region of Denmark (H-20028627) and (H-20079890). The human studies were conducted in agreement with the Helsinki declaration. We have received informed consent to do the examinations included in this study including to publish data.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. We have no restrictions with regards to data availability.</p></sec><supplementary-material><ext-link xlink:href="elife-70002-supp-v2.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>